Early research (Phase 1)Study completedNCT04519437
What this trial is testing
Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Repeated Subcutaneous Doses of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (REGN10933+REGN10987) in Adult Volunteers as Related to COVID-19
Who this might be right for
HealthyChronic Stable Illness
Regeneron Pharmaceuticals 974